Jelly Roll Capital Equity Research

Market Analysis, Education, and Wall Street-Quality Stock Reports

Aspreva

This report covers biotechnology company Aspreva Pharmaceuticals (ticker: ASPV). Aspreva has since been bought out.

Features of this research report:

· 13 pages

· An extensive examination of Aspreva’s operating activities and clinical trials, including potential drivers of future growth

· Analysis of Aspreva’s current financial state

· Discussion of the risks and other challenges the company will be facing

· A look at the profitability of Aspreva using metrics we feel present a more accurate view of the company than the simple Price-to-Earnings (P/E) ratio

· Calculations to show management’s efficiency at using capital to generate shareholder value

· Estimate of intrinsic value using discounted cash flow (DCF) modeling

· Breakdown of what the current price of Aspreva’s stock implies about the market’s expectations

Released 2-27-2007

Cover page of our report on Aspreva

To contact us:

Please include a relevant reference in the subject

heading line.

 

 

research@valuestockreports.com

 

 heading line.